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Department of Medicine, The Johns Hopkins University School of Medicine at The Good Samaritan Hospital, 
O'Neill Research Laboratories, Baltimore, Maryland, U. S. A. 
Release of eosinophil chemotactic factor (ECF) and histamine was studied in peripheral 
leukocytes of 16 normal and 12 ragweed allergic volunteers and compared to 15 patients with 
chronic urticaria. Cells were exposed to varying concentrations of anti-IgE or to ragweed 
antigen E in the case of allergic donors. Twelve of 15 patients with chronic urticaria showed 
defective release of ECF as well as histamine, while almost all normal and all allergic donors 
were able to release larger quantities of both mediators. Since the eosinophil is thought to 
have a modulating effect at sites of inflammation induced by anaphylactic mechanisms, the 
defective release of a factor attracting these cells may explain the persistence of symptoms in 
chronic urticaria. 
Immunologic reactions of the immediate type 
are associated with the release of mediators from 
mast cells and basophils. Urticaria is a cutaneous 
manifestation of this type of reaction and can be 
induced with a variety of allergens and by physico-
chemical means. For chronic urticaria, defined as a 
recurrence of lesions at frequent intervals over 
more than 6 weeks, a cause can be found only in a 
small percentage of cases [1]. 
While studying the release of mediators from 
basophils in these patients, Greaves et al [2] noted 
that they release considerably less of the histamine 
stored in their basophils by methods of reverse 
anaphylaxis (i.e., anti-IgE) in contrast to normal 
individuals. These findings were confirmed in our 
laboratory [3], but the significance and mech-
anisms underlying this observation have not been 
clarified. In the present study, an attempt was 
made to further define this problem by examining 
whether the release of another mediator from 
basophils, the eosinophil chemotactic factor (ECF) 
[4], is also defective in patients with chronic urti-
cana. 
ECF-A is a low-molecular-weight peptide whose 
structure has recently been determined [5]. It can 
be released from tissue mast cells by reverse 
anaphylaxis [6]. A similar or identical factor (ECF) 
is released from normal human basophils by the 
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same method [4] or by the calcium ionophore 
A23187 [7] and from human neutrophils by the 
ionophore [8 J or by phagocytosis [9 J. 
MATERIALS AND METHODS 
Fifteen patients with chronic urticaria of unknown 
cause which had persisted for more than 6 weeks were 
studied together with 16 normal volunteers and 12 
ragweed allergic individuals. None of the subjects re-
ceived any medication for at least 3 days prior to testing. 
The method for mediator release has been described in 
detail [4] . Briefly, venous blood was drawn into ethylene-
diaminetetraacetic acid (EDT A) and leukocytes were 
allowed to sediment in 6% dextran for 2 to 3 hr. The 
supernatant containing leukocytes and platelets in 
plasma was then aspirated, centrifuged gently to remove 
platelets , and the leukocytes were washed twice in Tris 
buffer (pH 7.4) containing human albumin (0.03%). For 
release of mediators, aliquots of these cells were incu-
bated in Tris-albumin buffer with added calcium (0.6 
mM) and magnesium (1.0 mM) and were exposed to 
varying concentrations of highly purified antihuman IgE, 
prepared as described previously [10]. Ragweed antigen 
E (a gift of Dr. T. P. King) [11] was used for release from 
leukocytes of allergic donors . After 30 min of incubation 
at 37°C, cells were separated from the supernatants by 
centrifugation at 400 g for 5 min, and the supernatants 
were tested for histamine and ECF activity. 
Histamine determinations were performed in dupli-
cate by a spectrophotofluorometric technique [12]. Total 
cellular histamine content was · obtained by lysis or 
sonication of cells, and the amount of antigen-induced 
release was expressed as percentage of the total. For ECF 
determinations, supernatants were placed in the lower 
part of a modified Boyden chamber, and 2.5 x 106 
purified human or guinea-pig eosinophils were placed 
above a nitrocellulose filter (Sartorius Membran Filter 
GMBH, Gottingen, Germany) . After 3 hr of incubation at 
37°C in 100% humidity, the filters were stained, dried, 
and cleared in m-Xylene (Eastman Kodak, Rochester , 
NY) . Eosinophils that had migrated completely through 
the filters were counted under high-dry magnification. 
All samples were tested at least in duplicate. Details of 
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this method have been published elsewhere [4,8] . Periph-
eralleukocyte counts were performed by examining fresh 
smears stained with Wright's stain and by counting 100 
cells with a high-dry objective under the microscope. 
RESULTS 
The Figure shows the typical release curves for 
histamine and ECF at increasing anti-IgE concen-
tration in a healthy control and a patient with 
urticaria. As previously described [4], histamine 
and ECR release from basophils of normal or 
allergic individuals follow parallel dose-response 
curves with depression of release in the region of 
antigen excess. The patient with chronic urticaria, 
in this case, however, releases less than 5% of the 
total histamine content from his peripheral baso-
phils and, under the same conditions, very little 
ECF release was observed. It was not possible to 
express the ECF activity as percent of total cellular 
content because, unlike histamine, very little or no 
ECF is released from basophils on sonication [13], 
and inhibitors of ECF are liberated from other cells 
present in the buffy coat [14]. ECF release was 
therefore expressed in terms of a threefold increase 
at optimal stimulation over that induced by the 
least effective stimulus. The difference between 
control values and a threefold increase of ECF 
activity had a p value of <0.001 in all subjects 
with normal histamine release curves. 
The Table summarizes all the results obtained. 
The number of subjects showing a greater than 
threefold increase in ECF release and a more than 
25% of total cellular histamine release is compared 
in the three groups studied. All allergic patients 
were able to release significant amounts of media-
tors on antigen E stimulation, and almost all nor-
mal subjects could equally be induced to release 
the mediators after anti-IgE challenge of their pe-
ripheral leukocytes. In contrast, the cells of only 3 
of .15 patients with chronic urticaria behaved like 
normal cells after anti-IgE stimulation, and 12 re-
leased little or no histamine of ECF. The release 
curves for these two mediators at different anti-IgE 
concentrations were therefore flat in the latter 
indi vid uals. 
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TABLE. Mediator release from peripheral leukocytes in 
normal volunteers and in patients with ragweed allergy 
and chronic urticaria 
Histamine release (HR) of more than 25% and ECF 
release showing a more than threefold increase above 
baseline is considered normal. 
Subjects Releasing Noo of 25%HR 3 x ECF agent patients 
Normal Anti-IgE 16 14 15 
Allergic Antigen E 12 12 12 
Urticaria Anti-IgE 15 3 3 
The total histamine content of basophils was in 
the range of normal for patients and control sub-
jects. Total ECF content could not be measured for 
the reasons outlined above [4,8,13]. 
Differential counts of peripheral leukocytes 
showed no eosinophilia (> 4 %) in any of the 
chronic urticaria patients. 
DISCUSSION 
The decreased histamine release from basophils 
of chronic urticaria patients by reverse anaphy-
laxis is an intriguing finding, the underlying defect 
for which is not apparent. After extensive studies 
in this laboratory, a "desensitization" of the cell 
has been suggested as the most likely cause [3]. 
The finding that mediators other than histamine 
are also not released during anti-IgE challenge 
suggests that the secretory mechanism of the cell, 
at least as it relates to the release of the mediators 
of anaphylaxis, is generally suppressed. Our previ-
ous studies demonstrated that the number of 
circulating basophils in the peripheral blood of the 
patients is normal [3]. Also, several investigators 
reported normal [15] or only slightly elevated [2,3] 
serum IgE levels, and the cyclic AMP levels of 
peripheral leukocytes did 'not differ from those of 
controls [3 J. 
Many chemical inhibitors of mediator release 
from basophils are known [16]. Histamine, when it 
reaches a certain concentration, inhibits further 
histamine release by elevating cyclic AMP in the 
cell [17], and elevated serum histamine levels have 
been demonstrated in patients with urticaria (18]. 
Beta-adrenergic agents such as epineprine also 
inhibit histamine formation so that it is possible 
that the decreased response is due to circulating 
hormones [16]. On the other hand, patients with 
chronic urticaria may be thought of as being 
intermittently exposed to stimuli which activate 
the cellular release mechanism and lead to a 
refractory or desensitized state. 
Eosinophils are prominent in many allergic reac-
tions and have been observed to be elevated in 
urticarial reactions associated with parasitism, 
serum sickness, and drug reactions. They are 
thought to have a modulating effect on allergic 
reactions, and they are reported to contain an 
inhibitor of histamine release [19] and an inactiva-
tor of another mediator, the slow-reacting sub-
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stance of anaphylaxis [20]. The significance of a 
defective release of a factor (ECF) attracting these 
cells to sites of inflammation can only be specula-
tive, but may partly explain the persistence and 
chronicity of symptoms in patients with chronic 
urticaria." It is of interest, finally, that the defect in 
release in these patients is concordant with respect 
to both a preformed mediator, histamine, and ECF 
which is generated after the immunologic stimuli 
[13 ]. 
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